WHO-ILAE-IBE: Optimizing care: Epilepsy and pregnancy in women and girls

The possible effect of antiseizure medication on the unborn child has implications for women and girls with the potential of pregnancy. Specifically, valproic acid (sodium valproate) is a commonly prescribed medication. However, its use in women and girls who want to or may become pregnant raises significant concerns due to the elevated risk of birth defects and developmental disorders in children exposed to the drug in utero. There is a 10% risk of foetal malformation and a 30 to 40% risk of neurodevelopmental difficulties in children born to women taking valproate through pregnancy. Recognizing these risks, WHO guidelines emphasize the importance of informed decision-making and careful management in this population. This webinar aims to explore best practices and challenges in prescribing to women and girls with epilepsy, with a focus on mitigating risks and ensuring safety.

Webinar goals

• Inform about WHO’s updated mhGAP guidelines on the use of valproic acid (sodium valproate) for the treatment of epilepsy in women and girls who want to or may become pregnant
• Raise awareness among stakeholders about the relative risks of prescribing in women and girls and provide guidance on treatment options
• Highlight the importance of shared decision-making and individualized care when managing epilepsy in women planning pregnancy, or already pregnant

Organizers

• World Health Organization (WHO)
• International League Against Epilepsy (ILAE)
• International Bureau for Epilepsy (IBE)